<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[lilly Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/lilly.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to lilly]]></description>
	<s:counts start="0" returned="20" found="233" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Lilly's Job Cuts Not Enough for Wall Street; Another Merger Suggested; CEO Lechleiter Eats a Steak]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10004335/lillys-job-cuts-not-enough-for-wall-street-another-merger-suggested-ceo-lechleiter-eats-a-steak/]]></link>
		<description><![CDATA[Eli Lilly's announcement that it wants to get rid of 5,500 employees to get $1 billion in cost savings appears to have had no effect on its stock. Why would that be? Shouldn't Wall Street be rejoicing at an extra $1 billion heading toward the net income line and not...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Wed, 16 Sep 2009 16:36:38 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/job.html"><![CDATA[Job]]></category>
		<category domain="http://resources.bnet.com/topic/merger.html"><![CDATA[Merger]]></category>
		<category domain="http://resources.bnet.com/topic/net+income.html"><![CDATA[Net Income]]></category>
		<category domain="http://resources.bnet.com/topic/wall+street.html"><![CDATA[Wall Street]]></category>
		<category domain="http://resources.bnet.com/topic/lilly.html"><![CDATA[Lilly]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[Lilly's Zyprexa Costs Reach $3.3B; 6% of Revenues Since '06]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10003232/lillys-zyprexa-costs-reach-33b-6-of-revenues-since-06/]]></link>
		<description><![CDATA[Eli Lilly has finally admitted, albeit by omission, that the money it has paid out or set aside for legal claims related to Zyprexa is "meaningful." Previously, Lilly had labelled the settlement payments -- as much as $3.3 billion since 2006 -- as "not meaningful" on its quarterly income statements....]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Wed, 22 Jul 2009 13:55:16 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/revenue.html"><![CDATA[Revenue]]></category>
		<category domain="http://resources.bnet.com/topic/lilly.html"><![CDATA[Lilly]]></category>
		<category domain="http://resources.bnet.com/topic/operational+accounting.html"><![CDATA[Operational Accounting]]></category>
		<category domain="http://resources.bnet.com/topic/personal+finance.html"><![CDATA[Personal Finance]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[Sam's Enlists Debi Lilly in Plan to Boost Summer Sales]]></title>
		<link><![CDATA[http://industry.bnet.com/retail/10002425/sams-enlists-debi-lilly-in-plan-to-boost-summer-sales/]]></link>
		<description><![CDATA[Samâ€™s Club is taking the summer seriously, building on a membership initiative with a marketing campaign devoted to helping members get the most from the season.    Samâ€™s launched its 100 Days of Summer program as a $15 Memorial Day to Labor Day membership for consumer and small...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Mon, 15 Jun 2009 07:14:19 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/consumer.html"><![CDATA[Consumer]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/sam.html"><![CDATA[Sam]]></category>
		<category domain="http://resources.bnet.com/topic/lilly.html"><![CDATA[Lilly]]></category>
		<category domain="http://resources.bnet.com/topic/corporate+communications.html"><![CDATA[Corporate Communications]]></category>
		<category domain="http://resources.bnet.com/topic/marketing+research.html"><![CDATA[Marketing Research]]></category>
		<category domain="http://resources.bnet.com/topic/public+relations.html"><![CDATA[Public Relations]]></category>
		<category domain="http://resources.bnet.com/topic/marketing.html"><![CDATA[Marketing]]></category>
		<category domain="http://resources.bnet.com/topic/mike+duff.html"><![CDATA[Mike Duff]]></category>
	</item>
	<item>
		<title><![CDATA[Lilly Q1: Price Rises, End of Zyprexa Woes Boost the Numbers]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10001741/lilly-q1-price-rises-end-of-zyprexa-woes-boost-the-numbers/]]></link>
		<description><![CDATA[With its costly Zyprexa settlements out of the way, Eli Lilly got back to business as usual: Raising drug prices. And it seems to have paid off. Lilly's Q1 revenue was $5 billion, up from $4.8 billion the year before (but down sequentially from mid-2008 when quarterly revenues touched $5.2...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Mon, 20 Apr 2009 11:09:44 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/revenue.html"><![CDATA[Revenue]]></category>
		<category domain="http://resources.bnet.com/topic/lilly.html"><![CDATA[Lilly]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/sales+force+management.html"><![CDATA[Sales Force Management]]></category>
		<category domain="http://resources.bnet.com/topic/operational+accounting.html"><![CDATA[Operational Accounting]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[Lilly Advertises "Effient" Despite Lack of FDA Approval]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10001158/lilly-advertises-effient-despite-lack-of-us-fda-approval/]]></link>
		<description><![CDATA[Eli Lilly is advertising its new blood-thinner, Effient, even though it is not yet approved in the U.S. The drug also known as prasugrel is approved in Europe as "Efient," but ads in which the drug's name is spelled with two f's have appeared on the cardiologytoday.com web site. "Effient"...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Wed, 25 Feb 2009 08:17:58 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/advertisement.html"><![CDATA[Advertisement]]></category>
		<category domain="http://resources.bnet.com/topic/lilly.html"><![CDATA[Lilly]]></category>
		<category domain="http://resources.bnet.com/topic/effient.html"><![CDATA[Effient]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[Swiss Allege Price Fixing on Viagra and Cialis]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000958/swiss-allege-price-fixing-on-viagra-and-cialis/]]></link>
		<description><![CDATA[Swiss authorities have accused Pfizer and Eli Lilly of conspiring to fix prices for Viagra and Cialis. The news has created the best Bloomberg headline ever: "Pfizer, Lilly, Bayer Operated Erection-Drug Cartel, Swiss Say."    A couple of days ago BNET noted that Pfizer and Lilly appear to...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 10 Feb 2009 16:40:19 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/bayer+ag.html"><![CDATA[Bayer AG]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/viagra.html"><![CDATA[Viagra]]></category>
		<category domain="http://resources.bnet.com/topic/lilly.html"><![CDATA[Lilly]]></category>
		<category domain="http://resources.bnet.com/topic/vertical+industries.html"><![CDATA[Vertical Industries]]></category>
		<category domain="http://resources.bnet.com/topic/benefits.html"><![CDATA[Benefits]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/sales+force+management.html"><![CDATA[Sales Force Management]]></category>
		<category domain="http://resources.bnet.com/topic/enterprise+software.html"><![CDATA[Enterprise Software]]></category>
		<category domain="http://resources.bnet.com/topic/software.html"><![CDATA[Software]]></category>
		<category domain="http://resources.bnet.com/topic/human+resources.html"><![CDATA[Human Resources]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BAYR Y</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="tickers">BAYR Y,PFE</category>
	</item>
	<item>
		<title><![CDATA[Pfizer, Lilly Have Won the ED War; Bayer Wilts]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000890/pfizer-lilly-have-won-the-ed-war-bayer-wilts/]]></link>
		<description><![CDATA[Pfizer and Eli Lilly appear to have definitively won the erectile dysfunction war: their respective brands, Viagra and Cialis, both showed sales growth in Q4 2008 and for the full year. Lilly's growth was slightly faster, but it is coming off a smaller base.    Bayer's brand, Levitra,...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Fri, 06 Feb 2009 07:14:32 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/bayer+ag.html"><![CDATA[Bayer AG]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/viagra.html"><![CDATA[Viagra]]></category>
		<category domain="http://resources.bnet.com/topic/lilly.html"><![CDATA[Lilly]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/sales+force+management.html"><![CDATA[Sales Force Management]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BAYR Y</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="tickers">BAYR Y,PFE</category>
	</item>
	<item>
		<title><![CDATA[Amylin Battle Heats Up as Eastbourne Capital Touts Rival Directors' Slate to Icahn's]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000802/battle-for-amylin-heats-up-as-eastbourne-capital-touts-rival-directors-slate-to-icahns/]]></link>
		<description><![CDATA[Eastbourne Capital has proposed a five-member team of its own for Amylin's board. Carl Icahn proposed his own slate last week. Both sets of investors are unhappy with the company that has a joint venture with Eli Lilly on diabetes drug Byetta.    Eastbourne said of its move:...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Mon, 02 Feb 2009 15:08:09 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/slate.html"><![CDATA[SLATE]]></category>
		<category domain="http://resources.bnet.com/topic/eli+lilly+%2526+co..html"><![CDATA[Eli Lilly & Co.]]></category>
		<category domain="http://resources.bnet.com/topic/board.html"><![CDATA[Board]]></category>
		<category domain="http://resources.bnet.com/topic/director.html"><![CDATA[Director]]></category>
		<category domain="http://resources.bnet.com/topic/eastbourne+capital.html"><![CDATA[Eastbourne Capital]]></category>
		<category domain="http://resources.bnet.com/topic/amylin.html"><![CDATA[Amylin]]></category>
		<category domain="http://resources.bnet.com/topic/lilly.html"><![CDATA[Lilly]]></category>
		<category domain="http://resources.bnet.com/topic/corporate+governance.html"><![CDATA[Corporate Governance]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/corporate+law.html"><![CDATA[Corporate Law]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">LLY</category>
		<category domain="tickers">LLY</category>
	</item>
	<item>
		<title><![CDATA[Lilly Apologizes for Wrongful Zyprexa Promotion; Still Shovelling Cash Into Settlement Furnace]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000755/lilly-apologizes-for-wrongful-zyprexa-promotion-still-shovelling-cash-into-settlement-furnace/]]></link>
		<description><![CDATA[Another quarter, another $80 million in "not meaningful" charges for Eli Lilly. The company reported its Q4 2008 results yesterday, and as usual the income statement contained a lump devoted to money lost on "asset impairments, restructuring and other special charges."    With the new charge for $80...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Fri, 30 Jan 2009 08:15:07 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/revenue.html"><![CDATA[Revenue]]></category>
		<category domain="http://resources.bnet.com/topic/eli+lilly+%2526+co..html"><![CDATA[Eli Lilly & Co.]]></category>
		<category domain="http://resources.bnet.com/topic/settlement.html"><![CDATA[Settlement]]></category>
		<category domain="http://resources.bnet.com/topic/insurance+company.html"><![CDATA[Insurance Company]]></category>
		<category domain="http://resources.bnet.com/topic/lilly.html"><![CDATA[Lilly]]></category>
		<category domain="http://resources.bnet.com/topic/insurance.html"><![CDATA[Insurance]]></category>
		<category domain="http://resources.bnet.com/topic/operational+accounting.html"><![CDATA[Operational Accounting]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/corporate+insurance.html"><![CDATA[Corporate Insurance]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">LLY</category>
		<category domain="tickers">LLY</category>
	</item>
	<item>
		<title><![CDATA[More Zyprexa Trouble for Lilly as Insurers Want Money Too]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000620/more-zyprexa-trouble-to-come-for-lilly-as-insurers-want-money-too/]]></link>
		<description><![CDATA[Eli Lilly still faces a ton of legal action on its Zyprexa mismarketing, despite having paid a $1.4 billion settlement recently to state prosecutors and a separate $1.2 billion to settle individual patient plaintiffs.    That leaves insurance companies, who believe they were defrauded out of money when...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Wed, 21 Jan 2009 16:35:38 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[Patient]]></category>
		<category domain="http://resources.bnet.com/topic/insurance+company.html"><![CDATA[Insurance Company]]></category>
		<category domain="http://resources.bnet.com/topic/zyprexa.html"><![CDATA[Zyprexa]]></category>
		<category domain="http://resources.bnet.com/topic/lilly.html"><![CDATA[Lilly]]></category>
		<category domain="http://resources.bnet.com/topic/insurance.html"><![CDATA[Insurance]]></category>
		<category domain="http://resources.bnet.com/topic/financial+planning.html"><![CDATA[Financial Planning]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/corporate+insurance.html"><![CDATA[Corporate Insurance]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[In Zyprexa Settlement, Lilly Fritters Away 7.2 Percent of Revenues]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000607/in-zyprexa-settlement-lilly-fritters-away-12-percent-of-revenues/]]></link>
		<description><![CDATA[Eli Lilly is close to settling criminal and civil charges related to its mismarketing of Zyprexa for $1.4 billion, the New York Times reports. The settlement will mean that Lilly will have disgorged $3.1 billion in charges, mostly for Zyprexa, since 2006. That's about 7.2 percent of its revenues over...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Wed, 21 Jan 2009 08:15:35 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/revenue.html"><![CDATA[Revenue]]></category>
		<category domain="http://resources.bnet.com/topic/settlement.html"><![CDATA[Settlement]]></category>
		<category domain="http://resources.bnet.com/topic/period.html"><![CDATA[Period]]></category>
		<category domain="http://resources.bnet.com/topic/zyprexa.html"><![CDATA[Zyprexa]]></category>
		<category domain="http://resources.bnet.com/topic/lilly.html"><![CDATA[Lilly]]></category>
		<category domain="http://resources.bnet.com/topic/litigation.html"><![CDATA[Litigation]]></category>
		<category domain="http://resources.bnet.com/topic/operational+accounting.html"><![CDATA[Operational Accounting]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[Pharma Roundup: Pfizer's Acquisition Plans, Prasugrel's Big Day, and More]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000555/pharma-roundup-pfizers-acquisition-plans-prasugrels-big-day-and-more/]]></link>
		<description><![CDATA[Pfizer wants acquisitions, big and small. Prasugrel has a date with the FDA. New Year's blog feature bonanza. Farewell, Pharmalot. by John Maas]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Mon, 05 Jan 2009 17:09:28 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/acquisition.html"><![CDATA[Acquisition]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/lilly.html"><![CDATA[Lilly]]></category>
		<category domain="http://resources.bnet.com/topic/pharmalot.html"><![CDATA[Pharmalot]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="tickers">PFE</category>
	</item>
	<item>
		<title><![CDATA[Odds Improve for Lilly's Prasugrel-ImClone Gamble]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000524/odds-improve-for-lillys-prasugrel-imclone-gamble/]]></link>
		<description><![CDATA[A panel of the European Medicines Agency recommended the approval of prasugrel, Eli Lilly's new blood thinner, and such recommendations are usually followed by the agency within a couple of months, Reuters reports. The news is a significant win in Lilly's long campaign to get this drug to market. It...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Fri, 19 Dec 2008 07:23:31 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/gamble.html"><![CDATA[Gamble]]></category>
		<category domain="http://resources.bnet.com/topic/acquisition.html"><![CDATA[Acquisition]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[Patient]]></category>
		<category domain="http://resources.bnet.com/topic/lilly.html"><![CDATA[Lilly]]></category>
		<category domain="http://resources.bnet.com/topic/mergers+%2526+acquisitions.html"><![CDATA[Mergers & Acquisitions]]></category>
		<category domain="http://resources.bnet.com/topic/corporate+law.html"><![CDATA[Corporate Law]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/investment.html"><![CDATA[Investment]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[More Bad News for Lilly's Prasugrel]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000380/more-bad-news-for-lillys-prasugrel/]]></link>
		<description><![CDATA[The bleeding risks of Eli Lilly's new blood thinner, prasugrel, are less clear than the company thinks, according to a Cedars Sinai cardiologist. The drug -- which Lilly hopes will be huge -- is currently under review by the FDA but has suffered a series of delays that have set...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 11 Nov 2008 06:55:12 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[Patient]]></category>
		<category domain="http://resources.bnet.com/topic/lilly.html"><![CDATA[Lilly]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[Patient]]></category>
		<category domain="http://resources.bnet.com/topic/lilly.html"><![CDATA[Lilly]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[How Eli Lilly Waved Goodbye to $3.1 Billion]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000333/how-eli-lilly-waved-goodbye-to-31-billion/]]></link>
		<description><![CDATA[Eli Lilly employed a technical accounting term to describe the $1.4 billion Zyprexa settlement as "not-meaningful." While the payout to states over lawsuits that allege the drug was mismarketed is obviously very meaningful -- the company reported a net loss of $465.6 million this quarter -- the term highlights the...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Fri, 24 Oct 2008 09:49:23 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/revenue.html"><![CDATA[Revenue]]></category>
		<category domain="http://resources.bnet.com/topic/eli+lilly+%2526+co..html"><![CDATA[Eli Lilly & Co.]]></category>
		<category domain="http://resources.bnet.com/topic/quarter.html"><![CDATA[Quarter]]></category>
		<category domain="http://resources.bnet.com/topic/payout.html"><![CDATA[Payout]]></category>
		<category domain="http://resources.bnet.com/topic/lilly.html"><![CDATA[Lilly]]></category>
		<category domain="http://resources.bnet.com/topic/operational+accounting.html"><![CDATA[Operational Accounting]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/asset+management.html"><![CDATA[Asset Management]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/operational+planning.html"><![CDATA[Operational Planning]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/revenue.html"><![CDATA[Revenue]]></category>
		<category domain="http://resources.bnet.com/topic/eli+lilly+%2526+co..html"><![CDATA[Eli Lilly & Co.]]></category>
		<category domain="http://resources.bnet.com/topic/quarter.html"><![CDATA[Quarter]]></category>
		<category domain="http://resources.bnet.com/topic/payout.html"><![CDATA[Payout]]></category>
		<category domain="http://resources.bnet.com/topic/lilly.html"><![CDATA[Lilly]]></category>
		<category domain="http://resources.bnet.com/topic/operational+accounting.html"><![CDATA[Operational Accounting]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/asset+management.html"><![CDATA[Asset Management]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/operational+planning.html"><![CDATA[Operational Planning]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">LLY</category>
		<category domain="tickers">LLY</category>
	</item>
	<item>
		<title><![CDATA[Zacks Analyst Blog Highlights: Schlumberger Ltd., Amylin Pharmaceuticals, Inc., Eli Lilly & Co., Onyx Pharmaceuticals, Inc. and Diageo Plc]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_Oct_23/ai_n30929905]]></link>
		<description><![CDATA[CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Schlumberger Ltd. (NYSE: SLB), Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 23 Oct 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/amylin+pharmaceuticals+inc..html"><![CDATA[Amylin Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/blog.html"><![CDATA[blog]]></category>
		<category domain="http://resources.bnet.com/topic/diageo+plc..html"><![CDATA[Diageo Plc.]]></category>
		<category domain="http://resources.bnet.com/topic/eli+lilly+%2526+co..html"><![CDATA[Eli Lilly & Co.]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[FINANCE]]></category>
		<category domain="http://resources.bnet.com/topic/investment.html"><![CDATA[Investment]]></category>
		<category domain="http://resources.bnet.com/topic/lilly.html"><![CDATA[Lilly]]></category>
		<category domain="http://resources.bnet.com/topic/marketing.html"><![CDATA[MARKETING]]></category>
		<category domain="http://resources.bnet.com/topic/nasdaq+stock+market+inc..html"><![CDATA[Nasdaq Stock Market Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/newsletter.html"><![CDATA[newsletter]]></category>
		<category domain="http://resources.bnet.com/topic/nyse+euronext.html"><![CDATA[NYSE Euronext]]></category>
		<category domain="http://resources.bnet.com/topic/onyx+pharmaceuticals+inc..html"><![CDATA[Onyx Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/schlumberger+ltd..html"><![CDATA[Schlumberger Ltd.]]></category>
		<category domain="http://resources.bnet.com/topic/stock.html"><![CDATA[stock]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AMLN</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">DEO</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">LLY</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NDAQ</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ONXX</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">SLB</category>
		<category domain="tickers">AMLN,DEO,LLY,NDAQ,ONXX,SLB</category>
	</item>
	<item>
		<title><![CDATA[Pharma Roundup: Prasugrel Delays Fit FDA Trend; Pfizer Settles Celebrex Suits; and More]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000304/pharma-roundup-prasugrel-delays-fit-fda-trend-pfizer-settles-celebrex-suits-and-more/]]></link>
		<description><![CDATA[Lilly's Prasugrel not alone in FDA delays; Pfizer paying $894 million in Celebrex suits; Wikipedia #1 drug information source in Europe; Teva teaching about generic biologics through online game. by John Maas]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Fri, 17 Oct 2008 15:43:12 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/lilly.html"><![CDATA[Lilly]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/wiki.html"><![CDATA[Wiki]]></category>
		<category domain="http://resources.bnet.com/topic/games.html"><![CDATA[Games]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/online+communications.html"><![CDATA[Online Communications]]></category>
		<category domain="http://resources.bnet.com/topic/personal+technology.html"><![CDATA[Personal Technology]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/lilly.html"><![CDATA[Lilly]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/wiki.html"><![CDATA[Wiki]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/online+communications.html"><![CDATA[Online Communications]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="tickers">PFE</category>
	</item>
	<item>
		<title><![CDATA[In Light of Prasugrel Delay, Lilly-ImClone Deal Suddenly Makes Sense]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000302/in-light-of-prasugrel-delay-lilly-imclone-deal-suddenly-makes-sense/]]></link>
		<description><![CDATA[For those of you wondering why Eli Lilly would volunteer to have its stock crushed by the loss of cash and added debt required to buy ImClone, here's one idea: The deal makes more sense if Lilly believes that prasugrel -- a potential blockbuster blood thinner with the brand name...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Fri, 17 Oct 2008 09:46:57 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/lilly.html"><![CDATA[Lilly]]></category>
		<category domain="http://resources.bnet.com/topic/prasugrel%252feffient.html"><![CDATA[Prasugrel/Effient]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/lilly.html"><![CDATA[Lilly]]></category>
		<category domain="http://resources.bnet.com/topic/prasugrel%252feffient.html"><![CDATA[Prasugrel/Effient]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[BMS to Lilly re ImClone: "Thanks for the Cash, Suckers!"]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000264/bms-to-lilly-re-imclone-thanks-for-the-cash-suckers/]]></link>
		<description><![CDATA[Bristol-Myers Squibb CEO James M. Cornelius wrote this note today after the announcement that Eli Lilly and ImClone had agreed on the former's $6.5 billion, $70-a-share acquisition of the latter. Let's go through it line by line to see if there's a subtext, shall we?    After describing...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Mon, 06 Oct 2008 10:06:06 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/eli+lilly+%2526+co..html"><![CDATA[Eli Lilly & Co.]]></category>
		<category domain="http://resources.bnet.com/topic/translation.html"><![CDATA[Translation]]></category>
		<category domain="http://resources.bnet.com/topic/bristol-myers+squibb+co..html"><![CDATA[Bristol-Myers Squibb Co.]]></category>
		<category domain="http://resources.bnet.com/topic/lilly.html"><![CDATA[Lilly]]></category>
		<category domain="http://resources.bnet.com/topic/imclone.html"><![CDATA[ImClone]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[Biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/mergers+%2526+acquisitions.html"><![CDATA[Mergers & Acquisitions]]></category>
		<category domain="http://resources.bnet.com/topic/investment.html"><![CDATA[Investment]]></category>
		<category domain="http://resources.bnet.com/topic/financial+accounting.html"><![CDATA[Financial Accounting]]></category>
		<category domain="http://resources.bnet.com/topic/corporate+law.html"><![CDATA[Corporate Law]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BMY</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">LLY</category>
		<category domain="tickers">BMY,LLY</category>
	</item>
	<item>
		<title><![CDATA[BNET Focus on Antidepressants: Part 2, Controversies]]></title>
		<link><![CDATA[http://www.bnet.com/5208-14054-0.html?forumID=1&threadID=3756&messageID=17736&start=0]]></link>
		<description><![CDATA[BNET Focus on Antidepressants: Part 2, ControversiesRE: BNET Focus on Antidepressants: Part 2, ControversiesLilly responds: Dear Jim,I am writing to you regarding your article, "Focus on Antidepressants: Part 2, Controversies," posted yesterday (10/1) on Bnet.com, in which two facts were inaccurately reported on Lillyâ€™s practices around funding of the NPR...]]></description>
		<s:doctype><![CDATA[Discussion threads]]></s:doctype>
		<pubDate>Thu, 02 Oct 2008 10:16:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/lilly.html"><![CDATA[Lilly]]></category>
		<category domain="http://resources.bnet.com/topic/antidepressants.html"><![CDATA[Antidepressants]]></category>
	</item>
</channel>
</rss>
